Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Real-time Estimate Cboe BZX Other stock markets 15:03:41 09/12/2025 GMT			5-day change	1st Jan Change
5.995 ^USD	-2.36%		+22.15%	+25.47%

12-04	Vanda Says FDA Lifts Partial Hold on Tradipitant Motion-Sickness Study	MT
12-04	FDA Lifts Hold on Vanda Pharmaceuticals' Motion Sickness Drug	DJ

Transcript : Vanda Pharmaceuticals Inc., Q1 2025 Earnings Call, May 07, 2025

Published on 05/07/2025 at 01:46 pm BST - Modified on 06/12/2025 at 09:53 pm BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good afternoon, and welcome to the Quarter 1 2025 Vanda Pharmaceuticals, Inc. Earnings Conference Call. I am Frans, and I'll be the operator assisting

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Vanda Pharmaceuticals Inc.

12-04	Vanda Says FDA Lifts Partial Hold on Tradipitant Motion-Sickness Study	MT
12-04	FDA Lifts Hold on Vanda Pharmaceuticals' Motion Sickness Drug	DJ
12-04	Vanda Pharmaceuticals Inc. Announces that FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness	CI
11-28	Sector Update: Health Care Stocks Decline Friday Afternoon	MT
11-28	Sector Update: Health Care Stocks Mixed Premarket Friday	MT
11-28	Vanda Says FDA Extends Review of Partial Clinical Hold on Tradipitant in Motion Sickness	MT
11-28	Vanda Pharmaceuticals Inc. Provides Regulatory Update on Tradipitant for Motion Sickness	CI
11-28	Vanda Pharmaceuticals provides regulatory update on Tradipitant for motion sickness	RE
11-18	Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting	CI
11-17	Vanda Pharmaceuticals reports positive results for Tradipitant in preventing GLP-1 induced nausea and vomiting	RE
11-05	B. Riley Initiates Coverage on Vanda Pharmaceuticals With Buy Rating, $11 Price Target	MT
11-04	Vanda Pharmaceuticals Inc., Q3 2025 Earnings Call, Oct 29, 2025
10-29	Vanda Pharma Q3 sales rises, driven by Fanapt growth	RE
10-29	Vanda Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10-29	Vanda Pharmaceuticals Inc. Revises Earnings Guidance for the Full Year 2025	CI
10-08	Monumental Sports & Entertainment Taps Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena	CI
10-01	Vanda Enters Framework Agreement to Resolve Disputes With FDA	MT
10-01	Vanda Pharmaceuticals says FDA to expedite re-review of Tradipitant by Nov 26	RE
10-01	Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration	CI
10-01	Vanda Pharmaceuticals Drugs to Get More FDA Reviews to Resolve Legal Disputes	DJ
09-25	Vanda Pharmaceuticals Inc. Announces the Publication in Plos One of an Article Titled "Melatonin Agonist Tasimelteon (Hetlioz®?) Improves Sleep in Patients with Primary Asimelteon	CI
08-28	Vanda Pharmaceuticals Gets FDA Orphan Designation for VGT-1849 Billion	DJ
08-28	Vanda Pharmaceuticals Says Polycythemia Vera Treatment Granted Orphan Drug Designation by FDA	MT
08-21	Vanda seeks FDA commissioner review of outgoing CDER director's decision to uphold approval of two generic versions of Hetlioz	RE
08-21	Vanda Asks FDA Commissioner to Review Decision to Uphold Approval of Two Generic Versions of Hetlioz Drug	MT